论文信息 - Melanoma in 2013: Melanoma—the run of success continues

Melanoma in 2013: Melanoma—the run of success continues

In 2013, new insights on the molecular features of cutaneous melanoma provided a paradigm shift in our understanding of the biology of this disease. Exploiting immune checkpoint blockade and the use of BRAF-targeted or MAPK-targeted agents contributed to important progress in the treatment and management of cutaneous melanoma.

Dirk Schadendorf | Axel Hauschild | A. Hauschild | D. Schadendorf

[1] P. Gimotty,et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.

[2] W. Sellers,et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.

[3] Lynda Chin,et al. Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.

[4] D. Schadendorf,et al. TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[5] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[6] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[7] T. Graeber,et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. , 2013, The Journal of clinical investigation.

[8] K. Flaherty,et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9] J. Wolchok,et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.